Author: admin

  • ‘Magic mushroom’ ingredient may delay aging and extend lifespan

    ‘Magic mushroom’ ingredient may delay aging and extend lifespan



    Psilocybin, the active ingredient in psychedelic mushrooms, may have both anti-aging as well as mental health benefits.

    As revenues from the anti-aging market—riddled with hope and thousands of supplements—surged past $500 million last year, Emory University researchers identified a compound that actively delays aging in cells and organisms.

    A new study in Aging demonstrates that psilocin, a byproduct of consuming psilocybin, the active ingredient in psychedelic mushrooms, extended the cellular lifespan of human skin and lung cells by more than 50%.

    In parallel, researchers also conducted the first long-term in vivo study evaluating the systemic effects of psilocybin in aged mice of 19 months, or the equivalent of 60–65 human years. Results indicated that the mice that received an initial low dose of psilocybin of 5 mg, followed by a monthly high dose of 15 mg for 10 months, had a 30% increase in survival compared to mice who hadn’t received any.

    These mice also displayed healthier physical features, such as improved fur quality, fewer white hairs, and hair regrowth.

    While traditionally researched for its mental health benefits, this study suggests that psilocybin affects multiple hallmarks of aging by reducing oxidative stress, improving DNA repair responses, and preserving telomere length. Telomeres are the structured ends of a chromosome, protecting it from damage that could lead to the formation of age-related diseases, such as cancer, neurodegeneration, or cardiovascular disease. These foundational processes influence human aging and the onset of these chronic diseases.

    The study concludes that psilocybin may have the potential to revolutionize anti-aging therapies and could be an effective intervention in an aging population.

    “Most cells in the body express serotonin receptors, and this study opens a new frontier for how psilocybin could influence systemic aging processes, particularly when administered later in life,” says Louise Hecker, senior author on the study, and former associate professor at Emory, where the research was initiated and funded.

    While much of what researchers know about psilocybin relates to the brain, few studies have examined its systemic impacts. Many people associate psilocybin with the hallucinogenic impacts, but the majority of the cells in the body express serotonin receptors.

    “Our study opens new questions about what long-term treatments can do. Additionally, even when the intervention is initiated late in life in mice, it still leads to improved survival, which is clinically relevant in healthy aging,” adds Hecker, currently an associate professor at Baylor College of Medicine.

    This news comes on the heels of KFF’s recent report that US life expectancy is still below that of other countries similar in income and size, with an average lifespan of 78.4 years, compared to 82.5 years elsewhere. Not only was it the lowest, but as the lifespan in similar countries increased by 7.9 years from 1980-2022, the US life expectancy has only increased by 4.7 years.

    “This study provides strong preclinical evidence that psilocybin may contribute to healthier aging—not just a longer lifespan, but a better quality of life in later years,” says Ali John Zarrabi, director of psychedelic research at Emory’s psychiatry department.

    “As a palliative care physician-scientist, one of my biggest concerns is prolonging life at the cost of dignity and function. But these mice weren’t just surviving longer—they experienced better aging,” adds Zarrabi, co-investigator of the study.

    Zarrabi emphasizes the importance of further research in older adults, as well as the well-documented overlap between physical and mental health.

    “Emory is actively involved in Phase II and III clinical trials of psilocybin-assisted therapy for depression, and these results suggest we also need to understand psilocybin’s systemic effects in aging populations,” says Zarrabi.

    “My hope is also that if psilocybin-assisted therapy is approved as an intervention for depression by the FDA in 2027, then having a better quality of life would also translate into a longer, healthier life.”

    Funding for the study came from several awards, including the Imagine, Innovative, and Impact (I3) Award, Emory University School of Medicine; the Georgia CTSA NIH Award; and a grant from Emory’s Woodruff Health Sciences Center for Health in Aging.

    Source: Emory University

    Continue Reading

  • Rory McIlroy targets glory | The 153rd Open

    Rory McIlroy targets glory | The 153rd Open

    McIlroy arrives in good touch. He finished 13-under-par at last week’s Genesis Scottish Open, sharing second behind Chris Gotterup, and was straight into a practice round early on Monday morning after a four-hour sleep.

    Eleven years have passed since McIlroy lifted the Claret Jug at Royal Liverpool and believers in fate may note that The 143rd Open finished on 20 July, the same day action wraps up in Royal Portrush.

    Unlike each of his previous nine pre-Championship press conferences, McIlroy did not have to spend this one fielding questions about when he was going to win his next major.

    Instead, the inevitable and imponderable queries surrounded how McIlroy can raise himself to go again after achieving a lifetime ambition.

    “I think everyone could see over the last couple of months how I struggled with that,” he said.
    “I’ve done something that I’ve told everyone that I wanted to do, but then I still feel like I have a lot more to give. Talk about the pressure being off, yes, but anyone that sits up here at this table, we’re all competitors.


    “We all want to do better. We all think we can just get a little bit extra out of what we have.

    “It has been an amazing year. The fact that I’m here at Portrush with the Green Jacket, having completed that lifelong dream, I want to do my best this week to enjoy everything that comes my way, enjoy the reaction of the fans and enjoy being in front of them and playing in front of them.

    “But at the same time, I want to win this golf tournament, and I feel like I’m very capable of doing that.”

    To do so, he plans to throw himself into the goldfish bowl that could become this small corner of his homeland this week.

    Continue Reading

  • Ocean Planet Exploration And Taxonomy: Naming A Strange New Species

    Ocean Planet Exploration And Taxonomy: Naming A Strange New Species

    The glass sponge, Advhena magnifica, prior to being collected in 2016 at a depth of ~2,000 meters (6,560 feet). Scientists call this class of sponges “glass” because their skeletons are made of silica (glass). Their bodies contain fascinating tissues that consist of many nuclei within a single membrane, and these tissues help conduct electrical signals across the sponge making them able to respond quickly to external stimuli. Image courtesy of the NOAA Office of Ocean Exploration and Research, 2016 Deepwater Exploration of the Marianas.

    Editor’s note: one day we will begin a detailed exploration of ocean worlds other than our own. Hopefully they will be habitable – and inhabited. Given that we still find new life forms on Earth – things which also seem strange by comparison to what has already been discovered, we have along way to go – on this world. As such it make sense to practice the skills of exploration and discover on a world close to us and our tools. In so doing we need to develop some translatable skills that we can apply to the robotic and human exploration of these other worlds. Expeditions and discoveries as describe below still happen. And the more we look, the more we discover.

    This story is about the newly-named Advhena magnifica. How are we going to name the new life forms that we discover offworld? Will we use the same Latin-based binomial naming system that is used on Earth, perhaps adapt it with a new prefix or suffix, or pick another language? Or go digital? Something to think about.

    Oh yes: It is fun to note that these explorers see the link to astrobiology as well: “In the case of Advhena magnifica, the shape of this sponge is reminiscent of an alien, like in the movies, with what looks like a long thin neck, an elongated head, and huge eyes. Advhena is from the Latin advena, which means alien, but in the sense of visitor, foreigner, or immigrant. Of course we, humans, were the actual visitors to the sponge’s deep-sea home when we found this “magnificent alien.” While we haven’t “officially” given it a common name in our paper, “E.T. sponge” seems to fit.”


    In a paper published in 2020 , scientists identified and named a new genus and species of sponge: Advhena magnifica. It was sampled and seen during missions in the Pacific on NOAA Ship Okeanos Explorer.

    On July 25, 2017, while exploring a seamount during an expedition on NOAA Ship Okeanos Explorer, a team of deep-ocean explorers came upon an extraordinary seascape. Dr. Chris Mah of the Smithsonian National Museum of Natural History (NMNH) dubbed the scene the “Forest of the Weird.” That was due to the diversity of prominent sponges rising up on stalks with their bodies oriented to face the predominant current carrying tiny food particles.

    Among the different sponges within this alien-like community was one that could not be missed. Rising high on a stalk, this sponge had a body with two large holes. They’re oddly reminiscent of the large eyes of the alien from the beloved movie, E.T.: The Extra-Terrestrial.

    Turns out that this wasn’t the first time that scientists exploring via Okeanos Explorer had encountered this unusual sponge. In 2016, while exploring a seamount many miles to the west near the Mariana Trench, a sample of the sponge had been collected. It was sent to the NMNH for long-term care and study by researchers, setting the stage for this exciting—and charismatic—discovery.

    We caught up with Dr. Cristiana Castello Branco, a postdoctoral researcher who made the discovery of the “E.T. sponge.” She is studying under the guidance of Dr. Allen Collins, Director of the NOAA Fisheries National Systematics Laboratory located at NMNH.

    Cristiana prepares to enter the human occupied vehicle, for a dive. At the time of the sponge discovery, Cristiana was a PhD student at NMNH being supervised by NOAA Fisheries’ Dr. Collins. Image courtesy of Cristiana Castello Branco.

    How did you know you’d found a new type of sponge?

    It is a long process between when we first see a specimen and when we can give it a name. While we know very little about deep-sea sponges, we do know they are very abundant, so chances are often good that we will find new species. But to know you found a new one, you need to analyze the skeletal elements of the sponge, called spicules, in the lab using powerful microscopes. The types of spicules and how they are organized in the body vary across different types of sponges, and the spicules are what we use to make identifications. But on top of that, we have to compare what we see to all the known species of a particular genus to find out if it is known or new to science.

    For the “E.T. sponge,” I had started my studies with Allen by analyzing some specimens from the Atlantic region. I also decided to examine specimens from other parts of the world that were closely related to taxa I was describing in my thesis. Among these samples, I found a couple representatives of the glass sponge family Bolosomidae, including a big and beautiful sponge with an alien-shaped body. At first, I thought it would be a new species of Bolosoma (a genus I’d been working on during my thesis). Once I began to examine the sponge’s spicules, I realized that they were not the same as those from any known species.

    Scientists used a powerful scanning electron microscope (SEM) to get the detailed image on the left of the sponge’s spicules; in the image, the spiky tips of the spicule are about 20 micrometers across. Because sponge spicules are delicate and sometimes not complete, SEM imagery is often supplemented with scientific illustration. The illustration on the right shows the same spicules, drawn by Nick Bezio. As part of the completion of his degree in Scientific Illustration at California State University, Monterey Bay, Nick did an internship with Allen at NMNH. SEM image courtesy of Cristiana Castello Branco; illustration by Nick Bezio.

    How did you choose the scientific name, Advhena magnifica, for this new sponge?

    The scientific name for a new animal is always Latin or Greek. We usually try to associate the name to something unique about that species, or we can honor someone, the expedition name, or a locality.

    In the case of Advhena magnifica, the shape of this sponge is reminiscent of an alien, like in the movies, with what looks like a long thin neck, an elongated head, and huge eyes. Advhena is from the Latin advena, which means alien, but in the sense of visitor, foreigner, or immigrant. Of course we, humans, were the actual visitors to the sponge’s deep-sea home when we found this “magnificent alien.” While we haven’t “officially” given it a common name in our paper, “E.T. sponge” seems to fit.

    Like all biologic samples collected during Okeanos Explorer expeditions, the “E.T. sponge” collected in 2016 was archived in the collections of the National Museum of Natural History, Smithsonian Institution. In this image of the collected sample, the two holes of the sponge that give it an alien appearance are clearly visible. These holes, termed oscules, serve as openings out of which the sponge pumps water. The sponge is covered in even tinier pores where the water is drawn into the sponge. Bacteria and other small prey are captured in small chambers and the water is pumped out through a complex of canals and ultimately straight out of the oscules. Image courtesy of NMNH.

    What is the significance of discovering a new genus and species?

    Discovering new species of deep-sea sponges is fairly common, and while the group is very diverse, we still know very little about it. We don’t even know how many species we still have to discover in the deep ocean, but it is a big number. So, chances for new discoveries are good.

    When we find a new genus or species, we are helping to describe our planet’s marine biodiversity. That term refers to the variety of living organisms in the ocean, from bacteria and fungi to invertebrates and fish, all the way to marine mammals and birds. All of these organisms are intricately connected. By documenting and describing marine biodiversity, we are building a better understanding of life and the impact of humans on Earth (in this case, in the ocean).

    Also, a description of a new genus just emphasizes how little we know about the deep sea and deep-sea sponges.

    What role does the newly discovered sponge play in the ecosystem?

    Sponges are one of the most diverse and abundant groups of organisms on the bottom of the ocean, and they have huge impacts in the marine ecosystem. Many are large and provide structure in and around which other organisms live. Sponges are filter-feeding animals capable of maintaining the balance of micro flora and fauna and have important roles in transforming nitrogen and carbon in the ocean. As sessile (attached) animals, they defend themselves by producing chemical compounds that may be useful in treating human diseases. As such, the study of deep-sea sponge biodiversity provides a necessary basis for future environmental management decisions as well as bio-prospecting studies.

    How did you get into this line of work? Do you have any advice for young people interested in being a zoologist who discovers new species?

    When I was an undergrad, I started to work with sponges as an intern at Universidade Federal da Bahia in Brazil. It was an opportunity to work on the scientific collection of the university, and I fell in love with sponges then. After that, I followed with a master’s degree and then I studied deep-sea sponges during my Ph.D. work at Museu Nacional, Universidade Federal do Rio de Janeiro.

    As for advice for young people, apply for internships and try to figure out what most gets your attention and love. It is not that easy, but as long as you are doing what you really enjoy, it is worth it.

    Astrobiology, Oceanography,

    Continue Reading

  • Immunotherapy Advances and Challenges in T-Cell Lymphoma

    Immunotherapy Advances and Challenges in T-Cell Lymphoma

    A close-up of a red cell with a red blood cell in the backgroundI: © Bipul Kumar – stock.adobe.com

    While advancements in T-cell lymphoma therapies have lagged behind those in B-cell lymphomas, recent years have seen progress with multiple immunotherapeutic approaches being explored. These include checkpoint inhibitors targeting PD-1/PD-L1, macrophage checkpoint inhibitors targeting CD47, monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, recombinant fusion proteins, and chimeric antigen receptor (CAR) T-cell therapies. Despite promising results, unique challenges persist.1

    T-cell lymphomas are rare and highly heterogeneous, making clinical trial enrollment difficult. A significant concern is that malignant T cells often share surface markers with healthy T cells, raising the risk of T-cell aplasia and opportunistic infections. CAR T-cell therapies targeting antigens such as CD5, CD7, and CD30 show potential but face issues like fratricide during manufacturing and long-term immune suppression.

    FDA-approved therapies like denileukin diftitox (Lymphir)and innovative bispecific antibodies are reshaping treatment options, particularly in cutaneous T-cell lymphoma (CTCL).2 Stefan K. Barta, MD, MS, emphasized that combining immunotherapies with epigenetic or pathway-targeted agents may enhance efficacy and safety.

    In an interview with Targeted Oncology, Barta, director of the T-Cell Lymphoma Program, executive officer of the AIDS Malignancy Consortium, and associate professor of clinical medicine (hematology-oncology) at Penn Medicine in Philadelphia, Pennsylvania, discussed the evolving landscape of immunotherapies for T-cell lymphomas.

    Lymphoma: © David A Litman – www.stock.adobe.com

    Targeted Oncology: Can you describe the different types of immunotherapies currently being investigated or used for T-cell lymphoma?

    Barta: In T-cell lymphomas, we are a little behind compared with the B-cell lymphomas, but over the last decade, there have been different types of immunotherap[ies] used in T-cell lymphomas, and those can be classified into immunotherapies that target the surface antigens and immunotherapies that target more [of] the immune response. For example, through checkpoint inhibition, particularly inhibition of the T-cell checkpoints or the macrophage checkpoints—if you look at the checkpoint inhibitors, we have the T-cell checkpoint inhibitors targeting mainly PD-1 [and] PD-L1 that have some moderate activity in T-cell lymphomas. That is different depending on what subtype of T-cell lymphoma you’re dealing with. These agents are probably more effective in extranodal NK/T-cell lymphoma and in cutaneous T-cell lymphomas than they are in [peripheral T-cell lymphoma (PTCL)]. There’s always a small concern about hyperprogression that has been demonstrated with the use of these agents in smoldering [adult T-cell leukemia/lymphoma (ATLL)] and may also be occurring in other T-cell lymphoma subtypes, but is not really well characterized. But in general, they probably lend themselves very much to combinations, for example, with epigenetic therapies, and a lot of studies are ongoing there.

    We have the macrophage checkpoint inhibitors, where macrophage phagocytosis is regulated by an “eat me” and a “do not eat me” signal. And the “do not eat me” signal is often regulated by expression of CD47 on the tumor cells that then inhibit the macrophage phagocytosis. We can target those signals by blocking the “do not eat me” signal and/or giving an “eat me” signal. There are several drugs that are under investigation that have also some modest activity as single agents but may again lend themselves as drugs for combinatorial regimens.

    The most common approach is that we target the cell surface antigens, and we can do that with monoclonal antibodies. We have some of them approved, for example, in cutaneous T-cell lymphomas. We have a drug that targets CCR4, mogamulizumab [Poteligeo], that has led to a significant improvement for patients with mycosis fungoides and Sézary syndrome and also has activity in ATLL.

    We have a very successful [antibody-drug conjugate] that targets CD30, brentuximab vedotin [Adcetris], and that, particularly when combined with chemotherapy for anaplastic large cell lymphoma and other CD30-positive lymphomas, has shown an improvement in progression-free and overall survival.

    We have recombinant fusion proteins that combine a toxin with an antibody to deliver that toxin to cancer cells. And we have denileukin diftitox [Lymphir] approved for CTCL.

    We have a lot of bispecific monoclonal antibodies under investigation that hopefully will also move the field. Lastly, we have cellular therapies that target the cell surface antigen, such as CAR T-cell therapy. There have been several targets that have been explored and have already published data, particularly CD30, CD5, CD7, CD70, and TCRβ1. We have seen a lot of feasibility data, meaning we have had a lot of difficulties developing these drugs for T-cell lymphoma because there’s the concern of fratricide. These cells kill each other during the manufacturing process; the CAR T cells kill the other CAR T cells because they express the same antigen. And of course, T-cell aplasia, when the CAR T cells that target the malignant cells also unfortunately target the normal T cells—because the issue is that we have expression of the same antigens on normal cells as well as on the malignant cells—that can lead to T-cell aplasia that can be associated with severe, life-threatening infections, activation of otherwise latent viruses, or even occurrence of second malignancies. And these have been obstacles, but several studies have shown it is feasible and have shown some early promising results, and a lot of investigations are ongoing at present.

    What are just some of the most recent clinical trial results regarding immunotherapies in this space?

    The immunotherapy field is very wide, with a lot of different approaches that have been tried. There have been several approvals based on drugs that have shown at least a progression-free survival, if not an overall survival benefit with these approaches. The drugs that stand out and have changed the playing field are mogamulizumab, currently for the treatment of Sézary syndrome and mycosis fungoides—that is a monoclonal antibody against CCR4. The other drug that stands out and has changed the playing field is brentuximab [vedotin].

    And a lot of clinical trials are ongoing with bispecific monoclonal antibodies—for example, targeting CD30 and linking the CD30 monoclonal antibody, for example, to NK cells like CD16. We have seen promising clinical trial data there, especially when we use allogeneic NK cells to be reinfused during part of the treatment to enhance the activity of these bispecific antibodies.

    And a lot of research is going on with CAR T cells in T-cell lymphoma, particularly CD5 and CD7, where we have some promising early clinical data.

    What are some of the major challenges or limitations associated with immunotherapy in T-cell lymphoma?

    The major challenge is that the T cells are often the cells effecting the anticancer effect, and they are at the same time the malignant cells. S, targeting the cancer with T cells can be much more difficult than it is in other cancers, where the effector cell is not at the same time the malignant cell, particularly with CAR T-cell therapy.

    We are using T cells to target T cells, and that comes with the problem that many of these antigens are shared, leading either to killing of the effector cells of each other—leading to destruction of normal T cells that we do need. And T-cell aplasia is not compatible with long life, unfortunately. That is something that needs to be addressed.

    Also, some of the mechanisms [are] at the same time suppressors in tumor growth. We take these checkpoints off, and we may thereby lead to more aggressive presentation of the cancer, as we have seen in some of the T-cell lymphomas with checkpoint inhibition, particularly in ATLL, for example. So that adds an extra layer of complications that needs to be addressed, which makes it much more challenging and explains why we’re a little behind in T-cell lymphomas as compared to B-cell lymphomas.

    The other challenge is that T-cell lymphomas are very heterogeneous. We have over 26 subtypes at present, and they’re very rare. So, when you have only 10% to 15% of all lymphomas in the United States and Europe being T-cell lymphomas—they are more common in Asia, for example, where in some parts, 25% of the non-Hodgkin lymphomas are T-cell lymphomas—but still a rare disease. And you have the extra heterogeneity, so that for some diseases, you get to very small numbers, and it’s very difficult to then study an effect on these small patient subsets.

    What are some of the most critical adverse events seen with these?

    The main aspect is that when you kill the malignant T cells, you may also kill the normal T cells. That can lead to reactivation of latent viral infections such as [cytomegalovirus] or [Epstein-Barr virus (EBV)]. That can in turn lead to infections or things like macrophage activation syndrome or [hemophagocytic lymphohistiocytosis] or even an EBV-positive malignancy. Furthermore, other opportunistic infections are much more common. So, these need to be addressed very aggressively in terms of prophylactic therapy or monitoring for reactivation of these viruses—that is one of the major concerns.

    The other concern in terms of toxicity. For example, for CAR T-cell therapy, the usual CAR T-cell toxicities are cytokine release syndrome and neurological [adverse events]. That’s specifically for CAR T-cell therapies. For other immunotherapies—each different immunotherapy may have specific side effects that we see with specific drugs, and that can vary widely from neuropathy that can be seen with some of the antibody-drug conjugates, for example, skin rashes that can be seen with some of the monoclonal antibodies, or other autoimmune phenomena, which is another issue that can be seen with immunotherapies directed against T cells.

    Are there any emerging technologies or agents that you believe could significantly impact treatment?

    Emerging technologies are clearly the development of cellular therapies. That comprises CAR T cells, but there are other cells that can be used—for example, NK cells or subtypes of T cells that then overcome some of the obstacles that I had mentioned, like the T-cell aplasia—because we only target very specific subsets of the T cells with certain drugs. That’s clearly an area of research. That means we have to identify which are the best targets. So, we have several targets, and as T-cell lymphomas are a very heterogeneous group of diseases, not all of these targets may be applicable to a large population. We might get into very small subtypes. As I mentioned, targeting gamma delta T cells that constitute often a very aggressive subtype of T-cell lymphoma can be difficult, as this is an extremely rare cancer. We will have to pool resources to allow that research and get input from industry and multicenter and international collaborations to get this trial off the ground.

    The other areas of research are: How can we combine these immunotherapies with other agents to make them more effective or reduce toxicities? For example, epigenetic therapies hold a lot of promise in combination with some of the immunotherapies, but other pathway inhibitors may also be promising. As I said, either increasing efficacy or reducing toxicity of these therapies.

    REFERENCES:
    1. Barta SK. The Promise of Immunotherapies in T-Cell Lymphoma. Presented at: 12th Annual Meeting of the Society of Hematologic Oncology (SOHO 2024). September 4-7, 2024. Houston, TX.
    2. Citius Pharmaceuticals receives FDA approval for LYMPHIR™ (denileukin diftitox-cxdl) immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. News release. Citius Pharmaceuticals. August 8, 2024. Accessed July 8, 2025. https://tinyurl.com/48pj3x9z

    Continue Reading

  • Beyond The Hype: What Apple’s AI Warning Means For Business Leaders

    Beyond The Hype: What Apple’s AI Warning Means For Business Leaders

    A groundbreaking Apple research paper has sent shockwaves through the AI community, revealing serious limitations in today’s most advanced models, flaws that have gone undetected until now.

    The paper “The Illusion Of Thinking” shows that the “chain-of-thought” reasoning applied by advanced models like GPT-4, Deep Seek, and Claude Sonnet suffer from “complete accuracy collapse” when tasks become too complex.

    And the most worrying aspect seems to be that once tasks are complicated enough, throwing more processing power, tokens or data at them does little to help.

    This has obvious implications for big-picture ideas that we’ve become accustomed to hearing, such as AI solving huge challenges like climate change, energy shortages, or global poverty.

    Large Reasoning Models, or LRMs, are the problem-solving engines powering agentic AI. Some consider them to be a step on the path towards artificial general intelligence, AI that can apply its learning to any task, just like humans can. Huge amounts of investment have been made in developing them, as they are considered the most advanced and useful AI models available today.

    But does this mean billions of dollars worth of investment have been poured into what is essentially a technological dead end?

    I don’t think so. But I do believe there are important lessons to be learned for businesses and organizations looking to unlock the true potential of AI, so let’s take a closer look.

    Findings

    The headline premise of the report is that AI “thinking” may just be an illusion rather than a true, functioning mirror of the objective reasoning humans use to solve problems in the real world.

    This is supported by findings of “accuracy collapse,” which show that while LRMs excel at managing low-complexity tasks, as complexity increases, they eventually reach a point where they fail completely.

    Perhaps most unexpectedly, the models appear to throw in the towel, using fewer tokens and putting in less effort once the task becomes too complex.

    And even if they are explicitly told how to solve the problem, they will often fail to do so, casting doubt on our ability to train them to move past this behavior.

    These are important findings because, in business AI, the belief has often been that bigger is better, meaning bigger data, bigger algorithms and more tokens. Apple’s findings suggest that beyond a certain point, these benefits of scale dissipate and eventually break down.

    The implication is that usefulness also diminishes when AI is asked to perform tasks that are too complex, such as formulating broad, high-level strategies in chaotic real-world scenarios or complex legal reasoning.

    What Does This Mean For Businesses Today?

    Rather than an insurmountable obstacle, I see this as a signpost that generative language AI shouldn’t be treated as a magic bullet to solve all problems.

    For me, there are three key lessons here.

    Firstly, focusing the attention of AI on structured, low-to-mid complexity tasks is more likely to hit the sweet spot.

    For example, a law firm shouldn’t expect it to simply produce a winning case strategy for them. The problem is too complex and open-ended and will inevitably lead to generic, useless output once the model reaches a point where it can no longer reason effectively.

    The firm can, however, use it to extract relevant points from contracts, create summaries of relevant prior case law, and flag up risks.

    Secondly, it emphasizes the importance of the human-in-the-loop, the vital element of human oversight that’s needed to ensure AI is used responsibly and accountably.

    Thirdly, when “accuracy collapse” is a danger, learning to recognize the signs, such as a drop in token use as the model gives up its attempts at reasoning, is critical to mitigating its impact.

    Playing to the strengths of AI while cushioning against the impact of its weaknesses is the name of the game.

    So, Has AI Hit A Dead End?

    In my opinion, Apple’s research doesn’t herald a “dead end” or end-of-the-road scenario for AI. Instead, it should be used by businesses to help them focus on areas where they are likely to succeed and to understand where they should build resilience against AI failure.

    Understanding the limitations of AI shouldn’t stop us from benefiting from it. But it helps us avoid situations where serious harm or damage could be caused by reasoning collapse or just wasted time and money.

    Agentic AI has the potential to help in this regard, with its ability to deploy various tools to bridge the gaps in situations where reasoning alone is insufficient. Similarly, the concept of explainable AI is important because designing systems to be transparent means that when a collapse does occur, we will have a better understanding of what went wrong.

    Certainly, no one should expect AI to always work perfectly and produce the best solution to every possible problem. However, the more we understand it, the more we can leverage its strengths and the more likely we are to create genuine value.


    Continue Reading

  • Gaza: UNICEF mourns seven children killed queuing for water – UN News

    1. Gaza: UNICEF mourns seven children killed queuing for water  UN News
    2. Gaza officials say children killed in strike as Israeli military admits ‘error’  BBC
    3. 47 Palestinians killed since dawn as Gaza conflict death toll rises to 58,026  Dawn
    4. LIVE: Israel pounds Gaza as criticism grows of plans for camps in Rafah  Al Jazeera
    5. Gaza crisis deepens: Israeli strikes kill dozens at aid centre, water point; death toll surpasses 58,000 amid deadlocked ceasefire talks  Ptv.com.pk

    Continue Reading

  • India Presses China on Trade Amid Rare Earths Tensions

    India Presses China on Trade Amid Rare Earths Tensions

    India’s foreign minister said removing “restrictive trade measures and roadblocks” is essential to improving ties between New Delhi and Beijing, in a veiled reference to China’s export controls on rare earths.

    “Measures towards normalizing our people–to–people exchanges can certainly foster mutually-beneficial cooperation,” India’s External Affairs Minister Subrahmanyam Jaishankar told his Chinese counterpart Wang Yi in Beijing on Monday. “It is also essential in this context that restrictive trade measures and roadblocks are avoided,” he added, according to a statement released by the Ministry of External Affairs in New Delhi.

    Continue Reading

  • Colorful aquarium creature turns out to be a new species

    Colorful aquarium creature turns out to be a new species

    A beautiful turquoise‑and‑lilac sea creature that has been kept in hobbyist aquariums around the world for nearly two decades has finally been given a scientific species name.

    The modest crustacean hiding in plain sight turns out to be Cherax pulverulentus, an entirely new crayfish species no biologist had cataloged until now.


    Jiří Patoka of the Czech University of Life Sciences Prague and an international team realized the oversight while inspecting a shipment of Indonesian pets in 2023.

    Their detective work now ends years of speculation about the animal’s identity in the scientific community worldwide.

    Meet Cherax pulverulentus

    Ever since the early 2000s, importers have marketed the animal under nicknames such as “Blue Moon” and “Hoa Creek,” labels that lumped several look‑alike species together.

    Dealers moved thousands of specimens across Europe, the United States, Japan, and Indonesia, yet museum drawers remained empty of an official voucher specimen.

    Collectors recognized the flashy colors, but the mix of hues muddied any attempt to match the pet to known taxa. Without an authoritative description, conservation agencies could not track exports or assess wild harvest pressure.

    Field notes hinted that the mystery crayfish came from forested headwaters near Ayamaru Lake in the Bird’s Head Peninsula of western New Guinea.

    Border checkpoints rarely scrutinized small ornamental shipments, allowing animals to flow from creeks to storefronts without paperwork.

    Cherax pulverulentus has two forms

    The research team reports that purple‑form individuals sport turquoise bodies dusted with violet specks. Their joints and tail fans fade to a chalky white, producing an almost pastel appearance that appeals to aquarists.

    Blue‑form animals replace those lilac freckles with a deep navy background that drifts toward black around the claws.

    Bright orange stripes frame the abdomen and legs, giving the crayfish a stark, two‑tone look unique within the genus.

    Patoka and colleagues chose the species epithet pulverulentus, Latin for “covered with dust,” to capture these pinpoint spots.

    The name, Cherax pulverulentus, cements the animal’s singular identity and separates it from Cherax pulcher, a close relative described in 2015.

    Detective work in the lab

    Traditional morphometrics ranked claw shape, eye size, and rostrum length against 38 allied species. DNA barcoding of the mitochondrial COI gene then revealed at least 2 percent divergence from every known member of the genus.

    “This species has been exploited in the ornamental aquarium trade at least for 21 years,” wrote Patoka in the report. That long tenure outside science underscores how commercial networks can outpace taxonomy.

    A second line of evidence came from nuclear 28S sequences that grouped Cherax pulverulentus as a sister lineage to C. pulcher, yet still distinct enough to rule out color morph status.

    The dual approach gives regulators a clear diagnostic toolkit should confiscated shipments require forensic identification.

    New Guinea streams to aquariums

    In the wild, the dusty crayfish digs shallow burrows into sandy streambeds shaded by rainforest canopy. Water temperatures hover near 75°F, oxygen levels stay high, and leaf litter offers both shelter and food.

    The Bird’s Head Peninsula ranks as a biodiversity hotspot, yet many of its tributaries remain unsampled by crustacean specialists.

    Local fishers collect juveniles during the dry season when water levels drop, a practice that feeds the export pipeline but leaves population trends unknown.

    Little is published on the crayfish’s diet, growth rate, or breeding season. Patoka’s team calls for ecological studies that could inform sustainable quotas before demand removes more animals than nature can replace.

    Dumping Cherax pulverulentus

    During the survey, one dusty crayfish turned up in a thermal spring near Budapest, Hungary, evidence that at least one aquarist released an unwanted pet.

    Similar introductions have seeded invasive populations of marbled crayfish and signal crayfish across Europe.

    Non‑native crustaceans often carry the oomycete Aphanomyces astaci, the agent of crayfish plague, a disease lethal to indigenous European stocks. Even a handful of carriers can trigger a cascade that empties streams of native fauna.

    Thermal refuges give tropical species a foothold in colder climates. Once established, escapees outcompete local detritivores, alter nutrient cycling, and nibble on amphibian eggs, multiplying their ecological footprint.

    Why formal naming matters

    Legal frameworks that govern wildlife trade, such as CITES, depend on precise species lists.

    An unnamed organism cannot be added to an appendix, leaving customs officials powerless to intercept over‑harvested cargo.

    Taxonomic clarity also guides aquaculture biosecurity. Without diagnostic characters, hatchery operators may unknowingly mix species, breeding hybrids that compromise genetic integrity in the source range.

    What’s next for Cherax pulverulentus?

    Patoka’s group urges Indonesian authorities to map the crayfish’s distribution and to monitor harvest volumes.

    Citizen scientists photographing stream fauna with location tags could accelerate the search for hidden colonies.

    Aquarists can help by buying captive‑bred stock, quarantining new arrivals, and never releasing pets into local waterways.

    Responsible hobby practice will allow enthusiasts to enjoy the dusty crayfish’s colors without endangering ecosystems.

    The study is published in Zootaxa.

    —–

    Like what you read? Subscribe to our newsletter for engaging articles, exclusive content, and the latest updates. 

    Check us out on EarthSnap, a free app brought to you by Eric Ralls and Earth.com.

    —–


    Continue Reading

  • Dynamic Flow Self-Driving Lab Speeds Up Materials Discovery

    Dynamic Flow Self-Driving Lab Speeds Up Materials Discovery


    Register for free to listen to this article

    Thank you. Listen to this article using the player above.

    Researchers have demonstrated a new technique that allows “self-driving laboratories” to collect at least 10 times more data than previous techniques at record speed. The advance – which is published in Nature Chemical Engineering – dramatically expedites materials discovery research, while slashing costs and environmental impact.

    Self-driving laboratories are robotic platforms that combine machine learning and automation with chemical and materials sciences to discover materials more quickly. The automated process allows machine-learning algorithms to make use of data from each experiment when predicting which experiment to conduct next to achieve whatever goal was programmed into the system.

    “Imagine if scientists could discover breakthrough materials for clean energy, new electronics, or sustainable chemicals in days instead of years, using just a fraction of the materials and generating far less waste than the status quo,” says Milad Abolhasani, corresponding author of a paper on the work and ALCOA Professor of Chemical and Biomolecular Engineering at North Carolina State University. “This work brings that future one step closer.”

    Until now, self-driving labs utilizing continuous flow reactors have relied on steady-state flow experiments. In these experiments, different precursors are mixed together and chemical reactions take place, while continuously flowing in a microchannel. The resulting product is then characterized by a suite of sensors once the reaction is complete.

    “This established approach to self-driving labs has had a dramatic impact on materials discovery,” Abolhasani says. “It allows us to identify promising material candidates for specific applications in a few months or weeks, rather than years, while reducing both costs and the environmental impact of the work. However, there was still room for improvement.”

    Steady-state flow experiments require the self-driving lab to wait for the chemical reaction to take place before characterizing the resulting material. That means the system sits idle while the reactions take place, which can take up to an hour per experiment.

    “We’ve now created a self-driving lab that makes use of dynamic flow experiments, where chemical mixtures are continuously varied through the system and are monitored in real time,” Abolhasani says. “In other words, rather than running separate samples through the system and testing them one at a time after reaching steady-state, we’ve created a system that essentially never stops running. The sample is moving continuously through the system and, because the system never stops characterizing the sample, we can capture data on what is taking place in the sample every half second.

    “For example, instead of having one data point about what the experiment produces after 10 seconds of reaction time, we have 20 data points – one after 0.5 seconds of reaction time, one after 1 second of reaction time, and so on. It’s like switching from a single snapshot to a full movie of the reaction as it happens. Instead of waiting around for each experiment to finish, our system is always running, always learning.”

    Collecting this much additional data has a big impact on the performance of the self-driving lab.

    “The most important part of any self-driving lab is the machine-learning algorithm the system uses to predict which experiment it should conduct next,” Abolhasani says. “This streaming-data approach allows the self-driving lab’s machine-learning brain to make smarter, faster decisions, honing in on optimal materials and processes in a fraction of the time. That’s because the more high-quality experimental data the algorithm receives, the more accurate its predictions become, and the faster it can solve a problem. This has the added benefit of reducing the amount of chemicals needed to arrive at a solution.”

    In this work, the researchers found the self-driving lab that incorporated a dynamic flow system generated at least 10 times more data than self-driving labs that used steady-state flow experiments over the same period of time, and was able to identify the best material candidates on the very first try after training.

    “This breakthrough isn’t just about speed,” Abolhasani says. “By reducing the number of experiments needed, the system dramatically cuts down on chemical use and waste, advancing more sustainable research practices.

    “The future of materials discovery is not just about how fast we can go, it’s also about how responsibly we get there,” Abolhasani says. “Our approach means fewer chemicals, less waste, and faster solutions for society’s toughest challenges.”

    Reference: Delgado-Licona F, Alsaiari A, Dickerson H, et al. Flow-driven data intensification to accelerate autonomous inorganic materials discovery. Nat Chem Eng. 2025. doi: 10.1038/s44286-025-00249-z

    This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.

    Continue Reading

  • Jack Grealish: Football fan pleads guilty to single count of assault after ‘slapping’ Man City star during Manchester derby | Football News

    Jack Grealish: Football fan pleads guilty to single count of assault after ‘slapping’ Man City star during Manchester derby | Football News

    A football fan admitted assaulting Manchester City and England star Jack Grealish by slapping his face after the footballer insulted him, he claimed.

    Alfie Holt, 20, pleaded guilty to a single count of assault on Grealish, who he said had called him a “little ugly w*****”, after the Manchester derby in April, Manchester Magistrates’ Court heard.

    Holt, a Manchester United season ticket holder in the Stretford End, was also given a three-year Football Banning Order and fined £120, with £85 costs and a surcharge of £48.

    The defendant, of Droylsden, Tameside, told the court: “I did not expect him to say what he said to me and I have reacted. I regret it. That’s it.”

    Shazia Aslam, prosecuting, told the court Grealish was leaving the field after the Manchester derby at Old Trafford, which was broadcast on Sky Sports, with a sell-out crowd and was always a “contentious affair”.

    “Both sets of fans were very vocal, shouting abusive comments to rival players,” Ms Aslam said.

    The court heard that as players left the field, heading for the tunnel, Holt stood very close by, shouting abuse at Manchester City players.

    “As the complainant, Jack Grealish, a Manchester City player, enters the tunnel area, he hears the defendant shouting comments towards him. He turns and walks towards him. Both have an exchange of words.

    “As the complainant walks away, the defendant slaps the complainant across the face. There was no injury. He was arrested outside the stadium.”

    In a witness statement, Grealish told police he could not hear what the defendant was shouting due to the crowd noise, so he walked towards him and tried to engage in conversation and leaned in to speak to the defendant.

    He was still unable to hear, so he moved to walk away when he was slapped.

    After his arrest, Holt told police he had been drinking before the game “in town” and went to the match with his father. He told police he was shouting abuse at Manchester City players, including Phil Foden, who ignored him.

    He then shouted, “k*******” at Grealish, who reacted and a “verbal altercation took place,” the court heard.

    Holt told police Grealish said to him: “You little, ugly w*****,” and he “flipped” and reached out and slapped the footballer.

    Magistrates were shown a brief clip of the incident, which had no sound.

    Ms Aslam added: “The defendant uses force against a player. Players are extremely vulnerable to this sort of conduct and need to be protected.”

    Melanie Winstantley, defending, said Holt had no previous convictions and had never been arrested before, so the incident was completely out of character for him.

    His Manchester United season ticket, which he has had for 12 years, had already been revoked, which is a “significant punishment” to him.

    She added: “He’s admitted what he’s done, he’s owned what he’s done. It’s a very minor assault.”

    Ms Winstanley also said Grealish had “doubled back” after going into the tunnel to speak to Holt.

    She added: “He didn’t have to do that. It’s not unusual for players and fans to engage in banter at football matches. I’m not trying to excuse the behaviour.”

    Passing sentence, chairwoman of the magistrates’ bench Jill Hodges told the defendant she accepted Holt had pleaded guilty and he appeared to regret his actions, but there must be “punishment and deterrence” for such behaviour.

    The court heard fines cannot be deducted from Holt’s Personal Independence Payments, so his parents, who he lives with, have agreed to pay them in full within 28 days.

    Continue Reading